EE65 Budget Impact of Zanubrutinib for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia in the United States
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.317
https://www.valueinhealthjournal.com/article/S1098-3015(22)02521-9/fulltext
Title :
EE65 Budget Impact of Zanubrutinib for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02521-9&doi=10.1016/j.jval.2022.09.317
First page :
Section Title :
Open access? :
No
Section Order :
12122